智通财经网·2025-11-18 08:41Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Chaohui Pharmaceutical Co., Ltd., has received acceptance for the drug registration application of Polyethylene Glycol (3350) Electrolyte Powder by the National Medical Products Administration, indicating a significant step in expanding its product portfolio in the chronic constipation treatment market [1] Company Summary - Fosun Pharma's Polyethylene Glycol (3350) Electrolyte Powder is a chemical drug intended for the treatment of chronic constipation, excluding constipation caused by organic diseases [1] - The expected sales revenue for Polyethylene Glycol Electrolyte Powder in mainland China (excluding Hong Kong, Macau, and Taiwan) is approximately RMB 873 million in 2024, according to the latest data from IQVIA CHPA [1]